The Danish drugmaker said last week that the trials, which were designed to show that its semaglutide pill Rybelsus could slow progression of the brain-wasting disease by at least 20%, did not meet their goals.
Sign up here.
The joint studies showed some improvement in a few key biological measures of the disease, but the changes were small and not enough to make a difference in delaying cognitive decline.
Both trials showed that Rybelsus had no impact at all on the rate of decline in a clinical dementia score compared to a placebo after two years, according to results presented at the Clinical Trials in Alzheimer’s Disease meeting in San Diego.
Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment
